HK5495A - New use of 1,4-dihydropyridine derivatives - Google Patents

New use of 1,4-dihydropyridine derivatives

Info

Publication number
HK5495A
HK5495A HK5495A HK5495A HK5495A HK 5495 A HK5495 A HK 5495A HK 5495 A HK5495 A HK 5495A HK 5495 A HK5495 A HK 5495A HK 5495 A HK5495 A HK 5495A
Authority
HK
Hong Kong
Prior art keywords
formula
compound
blood
calcium
preparation
Prior art date
Application number
HK5495A
Other languages
German (de)
English (en)
Original Assignee
Sandoz Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag. filed Critical Sandoz Ag.
Publication of HK5495A publication Critical patent/HK5495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (4)

1. L'utilisation d'un composé de formule Idans laquelle
R1 signifie l'hydrogène,
R2 et R5 signifient indépendamment alkyle en C1 -C6 ,
R3 et R4 signifient indépendamment alcoxy en C1-C6,
R6 signifie l'hydrogène,
X signifie l'oxygène, pour la préparation d'un médicament approprié pour l'utilisation dans le traitement de l'athérosclérose.
2. L'utilisation d'un composé de formule 1 selon la revendication 1, pour la préparation d'un médicament approprié pour l'utilisation dans la prévention ou l'inhibition de la formation de plaques dans l'athérosclérose.
3. L'utilisation de l'ester isopropylique de l'acide 4-(2,1,3-benzoxadiazole-4-yl)-1,4-dihydro-2,6-diméthyl-3-méthoxycarbonyl-pyridine-5-carboxylique comme composé de formule I pour la préparation d'un médicament selon la revendication 1 ou 2.
4. L'utilisation de l'ester diéthylique de l'acide 4-(2,1,3-benzoxadiazole-4-yl)-1,4-dihydro-2,6-diméthyl- pyridine-3,5-dicarboxylique comme composé de formule I pour la préparation d'un médicament selon la revendication 1 ou 2.
HK5495A 1984-11-12 1995-01-12 New use of 1,4-dihydropyridine derivatives HK5495A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848428552A GB8428552D0 (en) 1984-11-12 1984-11-12 Organic compounds
PCT/EP1985/000597 WO1986002836A1 (fr) 1984-11-12 1985-11-08 Nouvelle utilisation de derives de 1,4-dihydropyridine et de leurs combinaisons avec des calcitonines

Publications (1)

Publication Number Publication Date
HK5495A true HK5495A (en) 1995-01-20

Family

ID=10569606

Family Applications (1)

Application Number Title Priority Date Filing Date
HK5495A HK5495A (en) 1984-11-12 1995-01-12 New use of 1,4-dihydropyridine derivatives

Country Status (14)

Country Link
EP (1) EP0202282B1 (fr)
JP (1) JPH0627069B2 (fr)
AT (1) ATE77952T1 (fr)
AU (1) AU586455B2 (fr)
CY (1) CY1794A (fr)
DE (1) DE3586321T2 (fr)
DK (1) DK332786A (fr)
GB (1) GB8428552D0 (fr)
HK (1) HK5495A (fr)
MY (1) MY102063A (fr)
PH (1) PH22606A (fr)
SG (1) SG79394G (fr)
WO (1) WO1986002836A1 (fr)
ZA (1) ZA858672B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103613584B (zh) * 2013-11-27 2016-04-27 沈阳药科大学 一种伊拉地平合成产物后处理的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2210667A1 (de) * 1972-03-06 1973-09-20 Bayer Ag Kondensiert aromatisch substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2335466A1 (de) * 1973-07-12 1975-01-30 Bayer Ag Alkoxyalkyl-1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DK149855C (da) * 1977-06-20 1987-04-21 Sandoz Ag Analogifremgangsmaade til fremstilling af 1,4-dihydropyridinderivater
BE886259A (fr) * 1979-11-23 1981-05-20 Sandoz Sa Nouveaux medicament a base de derives de la 1,4-dihydropyridine, pour le traitement de l'insuffisance cerebrovasculaire ou a action spamolytique
DE3015219A1 (de) * 1980-04-19 1981-10-22 Bayer Ag, 5090 Leverkusen 6-amino-4,5-dihydropyridin-3-carbonsaeureester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4442112A (en) * 1981-09-02 1984-04-10 Sandoz Ltd. Dihydropyridine derivatives useful in treating vascular headaches
DE3222367A1 (de) * 1982-06-15 1983-12-15 Bayer Ag, 5090 Leverkusen Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung
FR2528431B1 (fr) * 1982-06-15 1986-01-10 Sandoz Sa Nouveaux derives de la 1,4-dihydropyridine, leur preparation et leur utilisation comme medicaments
JPS597163A (ja) * 1982-07-02 1984-01-14 Yamanouchi Pharmaceut Co Ltd 抗動脈硬化剤
US4656181A (en) * 1982-11-24 1987-04-07 Cermol S.A. Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
EP0125803A3 (fr) * 1983-04-27 1987-01-21 FISONS plc Dihydropyridines pharmaceutiquement actives

Also Published As

Publication number Publication date
AU5199286A (en) 1986-06-03
WO1986002836A1 (fr) 1986-05-22
DK332786D0 (da) 1986-07-11
DE3586321D1 (de) 1992-08-13
SG79394G (en) 1994-10-14
ZA858672B (en) 1987-06-24
PH22606A (en) 1988-10-17
GB8428552D0 (en) 1984-12-19
DE3586321T2 (de) 1992-12-10
MY102063A (en) 1992-03-31
EP0202282A1 (fr) 1986-11-26
JPH0627069B2 (ja) 1994-04-13
AU586455B2 (en) 1989-07-13
DK332786A (da) 1986-07-11
ATE77952T1 (de) 1992-07-15
CY1794A (en) 1995-02-17
JPS62500785A (ja) 1987-04-02
EP0202282B1 (fr) 1992-07-08

Similar Documents

Publication Publication Date Title
Prewitt et al. Antihypertensive polar renomedullary lipid, a semisynthetic vasodilator.
Hay et al. A novel angiotensin-(1-7) glycosylated mas receptor agonist for treating vascular cognitive impairment and inflammation-related memory dysfunction
US5260321A (en) Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
Olesen A calcium‐dependent reversible permeability increase in microvessels in frog brain, induced by serotonin.
Mendell et al. Increased plasma enzyme concentrations in rats with functional ischaemia of muscle provide a possible model of Duchenne muscular dystrophy
US20060083798A1 (en) Composition of natural herb extract for treating cardiovascular disease and its method of preparation thereof
UA63032C2 (en) Drug for treating hypertension
EP0617963A1 (fr) Composition pour améliorer le métabolisme lipidique
Zurovsky et al. Antioxidants attenuate endotoxin-induced acute renal failure in rats
Jaques The effect of intravenous injections of heparin in the dog
Thomas et al. Myocardial morphology and blood flow distribution in chronic volume-overload hypertrophy in dogs
EP0202282B1 (fr) Nouvelle utilisation de derives de 1,4-dihydropyridine
IL91572A (en) Pharmaceutical preparations for the treatment of symptoms caused by injury to the veins
Wang et al. Effects of synthetic parathyroid hormone on hemodynamics and regional blood flows
Grupp et al. Benzodiazepine Ro 5-4864 increases coronary flow
Baker et al. Slow calcium channel blockers and the calcium paradox: comparative studies in the rat with seven drugs
White Primitive hominid canine from Tanzania
Labow et al. The effect of mono (2-ethylhexyl) phthalate on an isolated perfused rat heart-lung preparation
EP0337697B1 (fr) Utilisation d'un antagoniste des rècepteurs de la thromboxane A2 pour la fabrication d'un médicament destiné à traiter l'hypertension pulmonaire due a'une neutralisation de l'heparine induite par une protamine
DE69117879T2 (de) Arzneimittel für die Verhütung und Behandlung von Krankheiten der Kreislauforgane enthaltend Spiro-3-heteroazolidin-Verbindungen
Wells et al. The vasopressin response to centrally administered hypertonic solutions in the conscious rat.
Ohtsu et al. The effect of dexamethasone on chronic pulmonary oxygen toxicity in infant mice
AU694440B2 (en) Method for removal of residual microbicide from a percutaneous medical device
Nickerson A low dose of a calcium antagonist (nitrendipine) ameliorates cardiac and renal lesions induced by DOC in the rat
Panton et al. In vitro and in vivo studies of the effects of halogenated histidine analogs on Plasmodium falciparum

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)